Ocera Therapeutics, Inc. (NASDAQ:OCRX) Receives $4.50 Average Price Target from Analysts
Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) have been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $3.85.
Several brokerages have recently weighed in on OCRX. Aegis reissued a “buy” rating and issued a $3.00 price target on shares of Ocera Therapeutics in a research note on Monday, April 17th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. Finally, Zacks Investment Research cut Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 17th.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC acquired a new stake in shares of Ocera Therapeutics during the first quarter worth approximately $2,817,000. Hikari Power Ltd acquired a new stake in shares of Ocera Therapeutics during the first quarter worth approximately $328,000. Finally, Renaissance Technologies LLC increased its stake in Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 33,300 shares in the last quarter. Institutional investors own 20.85% of the company’s stock.
Ocera Therapeutics (OCRX) opened at 1.10 on Tuesday. The company’s market cap is $29.16 million. The stock’s 50 day moving average is $1.13 and its 200 day moving average is $1.15. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $3.15.
Ocera Therapeutics (NASDAQ:OCRX) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative return on equity of 175.02% and a negative net margin of 4,416.26%. On average, analysts predict that Ocera Therapeutics will post ($1.08) earnings per share for the current fiscal year.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.